White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective

Publications
Category:
Published on:
April 20, 2022

What Qualifies as an NGT?

NGTs is a term for a range of new, leading-edge therapies that:

  • Expand science
    NGTs employ an expanding number of scientific approaches to diagnose and treat disease, including gene therapy, cell therapy, RNA therapy, immunotherapy, and hybrids of these therapeutic models
  • Meet the significant unmet need
    NGTs have secured approval by the EMA and/or FDA to meet significant unmet medical needs or promise significant improvement in patient health over current standards of care
  • Gain expedited market access
    NGTs are often approved through the FDA’s Breakthrough Therapy, EMA Prime Review, Rare Disease, and other priority review pathways—often after expedited reviews and clinical trials based on surrogate endpoints

About This White Paper 

This white paper explores NGTs, the market access and commercial challenges facing these innovations, solutions to those challenges, as well as patient and clinical ethical considerations.

Download this white paper to learn more about: 
  • Classification of Next Generation Therapies 
  • Challenges in access and commercialization of Next Generation Therapies, from clinical to access and commercialization challenges 
  • Innovative solutions for Next Generation Therapies access 
  • Patients’ view and ethical concerns 

Related news

Multimedia May 10, 2022
VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development
Join the 2nd episode of VacciTalks where together with vaccine expert Roberto Camerini we will peek behind the scenes of vaccine development and get an insider look at the difficulties,(...)
Market Access
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Multimedia April 28, 2022
Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe
Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Clinical Market Access RWE
Publications April 20, 2022
White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective
In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.
Market Access
Publications March 31, 2022
Real-World Evidence: Five Facts You Need to Know
Learn more about RWD and its future challenges for Europe, we asked Romain Finas, Vice President of Real-World Evidence (RWE) at Alira Health, to share five facts that you need to know about it.
Market Access RWE
Publications March 25, 2022
Early Access Programs: Keys to Success
Discover Alira Health’s top five recommendations to building a successful Early Access Programs (EAP). 
Market Access
News March 22, 2022
Alira Health and HTAi Collaborate to Develop a Multi-Stakeholder Value Assessment Framework for Robotic-Assisted Surgery & Digital Health
Learn more about the new evidence-based guidance on HTA for Robotic-Assisted Surgery and Digital Health Technologies. 
Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.